Navigation Links
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
Date:1/23/2012

SEATTLE, Jan. 23, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists for the treatment of cancer, today announced the publication of preclinical data demonstrating that VTX-2337, the Company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. VTX-2337 directly activates human myeloid dendritic cells (mDCs), monocytes and natural killer (NK) cells resulting in the production of high levels of mediators known to orchestrate adaptive anti-tumor responses. Data were published in the journal Clinical Cancer Research.

(Logo: http://photos.prnewswire.com/prnh/20120123/SF39404LOGO)

The findings clearly distinguish TLR8 from other human TLRs. TLR8 is expressed on human monocytes, macrophages and mDCs circulating in blood and lymph nodes as well as on dendritic cells that are prevalent throughout the tumor microenvironment. Results demonstrate that the direct activation of mDCs by VTX-2337 results in a uniquely robust production of inflammatory cytokines and chemokines that increase cell mediated immunity and potentially enhance the anticancer effect of standard chemotherapy. Additionally, VTX-2337 has a direct effect on NK cells and augments antibody dependent cellular toxicity (ADCC), which supports the opportunity of combining VTX-2337 with monoclonal antibodies where ADCC contributes to clinical efficacy.

"These preclinical findings underscore the potential of a TLR8 agonist as a promising novel agent for cancer immunotherapy," said Mary L. Disis, M.D., professor of medicine in oncology at the University of Washington and associate dean of translational science at the UW School of Medicine, and co-author of the publication. "This research provides validation for current clinical trials evaluating VTX-2337 in combination with existing cancer treat
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... CARLSBAD, Calif., Feb. 27, 2015 Isis Pharmaceuticals, ... significantly outperformed both its pro forma net operating loss ... in a strong financial position.  Isis, significantly improved financial ... than $230 million in payments the Company received from ... for 2014 was a nearly 60% improvement over its ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... trial show those treated with,Prexige experienced significantly smaller ... Many patients with osteoarthritis also have high blood,pressure; ... risk[2],[3] , * Prexige approved in more than ... use in osteoarthritis patients , BASEL, Switzerland, June ...
... an AI Over Tamoxifen in,a Single Trial ... of the entire,population of a single trial has ... significantly improved by switching from,tamoxifen to anastrozole (Arimidex). ... published online in The,Journal of Clinical Oncology, confirms ...
Cached Medicine Technology:Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 6Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 2Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 3Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 4Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 5
(Date:2/27/2015)... According to court documents, Donna Pirolli was a ... and underwent a procedure during which a duodenoscope was ... the duodenoscope allegedly had not been properly cleaned, Donna ... (CRE). , A lawsuit has been proceeding ... of Ms. Pirolli alleging that Lutheran General Hospital was ...
(Date:2/27/2015)... Legislation passed today by the House ... to help prevent inappropriate prescriptions in Medicare Part ... the Integrity of Medicare Act (PIMA), introduced by ... (R-TX) and Ranking Member Jim McDermott (D-WA), recognizes ... epidemic and implement the right policies, said the ...
(Date:2/27/2015)... Winter is here, and with it comes harsh ... snow and ice can be harmful on a dog’s paws. ... Puppy Store is ready to help pet owners know what ... the winter time. , Ice melts can lead to several ... Ingestion of ice melt products may cause depression, loss of ...
(Date:2/27/2015)... February 27, 2015 The Dawn Greene Hospice, ... Manning Walsh Home (MMW) on the Upper East Side, was ... of New York, His Eminence Timothy Michael Cardinal Dolan. , ... Board of Directors and a member of the ArchCare Board ... Sean William O’Brien, O.Carm, executive director of MMW, and Christina ...
(Date:2/27/2015)... 2015 FACE Skincare~Medical~Wellness, a multiaward-winning ... a unique combination to take fifteen years off ... is a new treatment introduced that is the ... indicated to improve lines and wrinkles on the ... who suffers from the stubborn vertical lines between ...
Breaking Medicine News(10 mins):Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2Health News:The Puppy Store Helps Dogs Prepare for Harsh Winter Conditions 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:Face Skincare Announces New Combination Therapy 2
... Philadelphians are expected to join the Lupus WHAT: Foundation of America for ... information and refreshments to support the need ... and information about signs and symptoms, diagnosis and tips to ... available at no charge to everyone., ...
... with secure transmission of patient data ... from hospital EMR to web-based PHR, ... (ICW), a global leader in eHealth technology,solutions and Memorial Hospital ... phase of Project Anchor, an initiative led by,Dr. Charles Eaton, ...
... and Optimize Reconstruction Surgery, TORONTO, May 8 ... of real-time imaging and image guidance systems for,use ... surgeons at Duke,University Hospital in Durham, North Carolina ... reconstructive surgical procedures. Since,beginning to use SPY near ...
... May 8 Biopure Corporation,(Nasdaq: BPUR ) ... has received new funding of approximately $3.4 million ... being granted,through the Department of Defense for a ... of Polytrauma Combat Casualties,with Brain Injury and Concomitant ...
... Scientific,Corporation (NYSE: BSX ) today announced U.S. ... family of pacemakers. ALTRUA is Boston,Scientific,s most advanced ... size and battery longevity. It is the first ... which the,heart beats too slowly -- usually less ...
... IDMI ) today reported financial results for the ... consolidated,results of IDM Pharma, Inc. and its subsidiary, IDM ... $2.4 million, and net loss was,$12.1 million or $0.48 ... non-cash charges of $4.7 million related to the increase ...
Cached Medicine News:Health News:5th Annual World Lupus Day Philadelphians Take Part In a Global Rally of Support 2Health News:InterComponentWare Inc. and Memorial Hospital of Rhode Island Celebrate Milestone 2Health News:InterComponentWare Inc. and Memorial Hospital of Rhode Island Celebrate Milestone 3Health News:InterComponentWare Inc. and Memorial Hospital of Rhode Island Celebrate Milestone 4Health News:Leading Plastic Surgeons at Duke Adopt SPY 2Health News:Leading Plastic Surgeons at Duke Adopt SPY 3Health News:Leading Plastic Surgeons at Duke Adopt SPY 4Health News:U.S. Navy Receives Funding for Further Development of Hemopure(R) 2Health News:U.S. Navy Receives Funding for Further Development of Hemopure(R) 3Health News:Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers 2Health News:Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers 3Health News:Boston Scientific Announces FDA Approval of New Family of Advanced Pacemakers 4Health News:IDM Pharma Reports First Quarter Financial Results 2Health News:IDM Pharma Reports First Quarter Financial Results 3Health News:IDM Pharma Reports First Quarter Financial Results 4Health News:IDM Pharma Reports First Quarter Financial Results 5Health News:IDM Pharma Reports First Quarter Financial Results 6Health News:IDM Pharma Reports First Quarter Financial Results 7Health News:IDM Pharma Reports First Quarter Financial Results 8
... a broad selection of tip ... wide variety of ophthalmic procedures. ... packaged sterile, complete with a ... in the "off " position ...
... Accu-Temp Cauteries provide a broad ... cauterization in a wide variety ... use cautery is packaged sterile, ... to lock switch in the ...
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
... provide a broad selection of tip ... variety of ophthalmic procedures. Each single ... with a safety cap to lock ... when not in use, and carries ...
Medicine Products: